| Year |
Citation |
Score |
| 2019 |
O'Leary CA, Andrews RJ, Tompkins VS, Chen JL, Childs-Disney JL, Disney MD, Moss WN. RNA structural analysis of the MYC mRNA reveals conserved motifs that affect gene expression. Plos One. 14: e0213758. PMID 31206539 DOI: 10.1371/Journal.Pone.0213758 |
0.322 |
|
| 2017 |
Gao M, Li B, Sun X, Zhou Y, Wang Y, Tompkins VS, Xu Z, Indima N, Wang H, Xiao W, Gao L, Chen G, Wu H, Wu X, Kong Y, et al. Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma. Theranostics. 7: 3690-3699. PMID 29109769 DOI: 10.7150/Thno.18345 |
0.365 |
|
| 2016 |
Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP. PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Reports. PMID 27239040 DOI: 10.1016/J.Celrep.2016.05.015 |
0.385 |
|
| 2015 |
Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia. PMID 26648534 DOI: 10.1038/Leu.2015.334 |
0.396 |
|
| 2015 |
Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM, Jing X, Foor SD, Acevedo MR, Walsh SA, Tricot G, Zhan F, Janz S. Adoptive B-cell transfer mouse model of human myeloma. Leukemia. PMID 26202932 DOI: 10.1038/Leu.2015.197 |
0.318 |
|
| 2015 |
Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S. CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. Experimental Hematology & Oncology. 4: 9. PMID 25838973 DOI: 10.1186/S40164-015-0005-2 |
0.431 |
|
| 2015 |
Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC, Waldschmidt TJ, Janz S. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. Leukemia. 29: 233-7. PMID 25257990 DOI: 10.1038/Leu.2014.260 |
0.365 |
|
| 2015 |
Rosean TR, Tompkins VS, Sompallae R, Norian LA, Morse HC, Waldschmidt TJ, Janz S. Abstract A04: The tumor microenvironment is the main source of IL-6 for plasmacytoma development in mice. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-A04 |
0.35 |
|
| 2014 |
Reed SM, Hagen J, Muniz VP, Rosean TR, Borcherding N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE. NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas. Plos One. 9: e112126. PMID 25393878 DOI: 10.1371/Journal.Pone.0112126 |
0.739 |
|
| 2014 |
Eckers JC, Kalen AL, Sarsour EH, Tompkins VS, Janz S, Son JM, Doskey CM, Buettner GR, Goswami PC. Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells. Radiation Research. 182: 420-9. PMID 25229973 DOI: 10.1667/Rr13726.1 |
0.345 |
|
| 2014 |
Reed SM, Hagen J, Tompkins VS, Thies K, Quelle FW, Quelle DE. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. Cell Cycle (Georgetown, Tex.). 13: 1288-98. PMID 24621507 DOI: 10.4161/Cc.28202 |
0.744 |
|
| 2013 |
Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC, Sunderland JJ, et al. (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer Journal. 3: e165. PMID 24292417 DOI: 10.1038/Bcj.2013.61 |
0.303 |
|
| 2013 |
Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE. RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts. Plos One. 8: e80228. PMID 24282525 DOI: 10.1371/Journal.Pone.0080228 |
0.771 |
|
| 2013 |
Muniz VP, Askeland RW, Zhang X, Reed SM, Tompkins VS, Hagen J, McDowell BD, Button A, Smith BJ, Weydert JA, Mezhir JJ, Quelle DE. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes & Cancer. 4: 273-84. PMID 24167655 DOI: 10.1177/1947601913501074 |
0.727 |
|
| 2013 |
Tompkins VS, Han SS, Olivier A, Syrbu S, Bair T, Button A, Jacobus L, Wang Z, Lifton S, Raychaudhuri P, Morse HC, Weiner G, Link B, Smith BJ, Janz S. Identification of candidate B-lymphoma genes by cross-species gene expression profiling. Plos One. 8: e76889. PMID 24130802 DOI: 10.1371/Journal.Pone.0076889 |
0.359 |
|
| 2013 |
Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S. Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochemical and Biophysical Research Communications. 436: 660-5. PMID 23764397 DOI: 10.1016/J.Bbrc.2013.06.012 |
0.441 |
|
| 2013 |
Tompkins VS, Gu Z, Xu H, Tricot G, Zhan F, Janz S. Abstract B38: Targeting FOXM1 in multiple myeloma Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-B38 |
0.34 |
|
| 2012 |
Muniz VP, Zhang X, Reed SM, Tompkins VS, Smith T, Hagen JK, Fitzgerald M, Button A, Smith B, Zamba KD, Domann FE, Mezhir JJ, Weydert J, Askeland RA, Quelle DE. Abstract 712: Parf-1A (Partner of ARF isoform 1A) promotes oxaliplatin resistance and is a new prognostic marker of survival in pancreatic ductal adenocarcinoma Cancer Research. 72: 712-712. DOI: 10.1158/1538-7445.Am2012-712 |
0.738 |
|
| 2012 |
Reed S, Tompkins V, Hagen J, Thies K, Cryderman D, Wallrath L, Quelle D. Abstract 215: Mechanisms of p53 activation by NIAM, nuclear interactor of ARF and MDM2 Cancer Research. 72: 215-215. DOI: 10.1158/1538-7445.Am2012-215 |
0.729 |
|
| 2010 |
Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Molecular Cancer. 9: 97. PMID 20433747 DOI: 10.1186/1476-4598-9-97 |
0.352 |
|
| 2009 |
di Tommaso A, Hagen J, Tompkins V, Muniz V, Dudakovic A, Kitzis A, Ladeveze V, Quelle DE. Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Experimental Cell Research. 315: 1326-35. PMID 19331830 DOI: 10.1016/J.Yexcr.2009.01.010 |
0.767 |
|
| 2008 |
Hagen J, Tompkins V, Dudakovic A, Weydert JA, Quelle DE. Generation and characterization of monoclonal antibodies to NIAM: a nuclear interactor of ARF and Mdm2. Hybridoma (2005). 27: 159-66. PMID 18582208 DOI: 10.1089/Hyb.2007.0533 |
0.692 |
|
| 2008 |
Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, Sakamuro D. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism. Journal of Cellular Physiology. 216: 621-31. PMID 18348166 DOI: 10.1002/Jcp.21437 |
0.318 |
|
| 2007 |
Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A, Ladeveze V, Domann FE, Eischen CM, Quelle DE. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. The Journal of Biological Chemistry. 282: 1322-33. PMID 17110379 DOI: 10.1074/Jbc.M609612200 |
0.771 |
|
| 2006 |
Tompkins V, Hagen J, Zediak VP, Quelle DE. Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle (Georgetown, Tex.). 5: 641-6. PMID 16582619 DOI: 10.4161/Cc.5.6.2560 |
0.708 |
|
| 2005 |
Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, Quelle DE. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Molecular and Cellular Biology. 25: 1258-71. PMID 15684379 DOI: 10.1128/Mcb.25.4.1258-1271.2005 |
0.761 |
|
| 2003 |
Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, Horne MC, Quelle DE. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Molecular Cancer Research : McR. 1: 195-206. PMID 12556559 |
0.763 |
|
| Show low-probability matches. |